Effect of Superior Laryngeal Nerve Blocks on Patient Outcomes in Laryngeal Surgery
Launched by RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY · Dec 10, 2024
Trial Information
Current as of August 21, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a numbing injection called a superior laryngeal nerve block on patients who are having surgery for vocal cord problems, such as vocal cord disease, polyps, or cysts. During the trial, some patients will receive the numbing injection to help reduce pain and coughing after surgery, while others will receive a saline injection, which is just a saltwater solution. The goal is to see how these different injections affect recovery, including pain levels and improvements in voice quality.
To be eligible for the trial, participants must be at least 18 years old, speak either English or Spanish, and have a benign (non-cancerous) vocal fold lesion that requires surgery. They should not be pregnant and must be able to provide consent to participate. While the trial is not yet recruiting participants, those who join can expect to be monitored for their symptoms after surgery to help determine which injection method works best for healing and voice recovery.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient is aged 18 years or older at time of consent
- • Patient has suspected or confirmed benign vocal fold lesion
- • Patient is planning to undergo direct laryngoscopy with excision of the vocal fold lesion
- • Patient is English or Spanish speaking
- • Patient is not pregnant per self report
- • Patient is not incarcerated
- Exclusion Criteria:
- • Patient is not 18 years of age or older at consent date
- • Patient does not speak English or Spanish
- • Patient is currently pregnant or plans to become pregnant prior to their study procedure
- • Patient has a laryngeal malignancy or found to find a laryngeal malignancy on final pathology
- • Patient will not be undergoing direct laryngoscopy with excision of lesion
- • Patient is unable to provide consent or complete study activities
- • Patient is incarcerated
About Rutgers, The State University Of New Jersey
Rutgers, The State University of New Jersey, is a prestigious public research university renowned for its commitment to advancing medical science and public health. As a leading clinical trial sponsor, Rutgers leverages its extensive academic resources, cutting-edge facilities, and a diverse team of experts to conduct innovative research that addresses critical health challenges. The university fosters collaboration across disciplines, engaging in partnerships with healthcare institutions and industry leaders to enhance the development of novel therapies and improve patient outcomes. With a strong emphasis on ethical standards and regulatory compliance, Rutgers is dedicated to advancing clinical knowledge while prioritizing participant safety and well-being in all of its research endeavors.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Newark, New Jersey, United States
Patients applied
Trial Officials
Kenneth Yan, MD, PhD
Principal Investigator
Rutgers, The State University of New Jersey
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported